Positive News SentimentPositive NewsNASDAQ:EGRX Eagle Pharmaceuticals (EGRX) Stock Price, News & Analysis → Warning: this could blow your mind (From DTI) (Ad) Free EGRX Stock Alerts $5.24 +0.23 (+4.59%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$4.96▼$5.3750-Day Range$4.42▼$6.5152-Week Range$4.10▼$32.44Volume80,452 shsAverage Volume129,101 shsMarket Capitalization$68.07 millionP/E Ratio4.44Dividend YieldN/APrice Target$17.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Eagle Pharmaceuticals alerts: Email Address Eagle Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingSell1.00 Rating ScoreUpside/Downside224.4% Upside$17.00 Price TargetShort InterestBearish10.15% of Float Sold ShortDividend StrengthN/ASustainability-2.29Upright™ Environmental ScoreNews Sentiment1.87Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.20 out of 5 starsMedical Sector216th out of 939 stocksPharmaceutical Preparations Industry94th out of 442 stocks 2.5 Analyst's Opinion Consensus RatingEagle Pharmaceuticals has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no buy ratings, no hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $17.00, Eagle Pharmaceuticals has a forecasted upside of 224.4% from its current price of $5.24.Amount of Analyst CoverageEagle Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted10.15% of the float of Eagle Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverEagle Pharmaceuticals has a short interest ratio ("days to cover") of 5.Change versus previous monthShort interest in Eagle Pharmaceuticals has recently increased by 4.50%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldEagle Pharmaceuticals does not currently pay a dividend.Dividend GrowthEagle Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreEagle Pharmaceuticals has received a 53.97% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Bendamustine", "Dantrolene", and "Pemetrexed" products. See details.Environmental SustainabilityThe Environmental Impact score for Eagle Pharmaceuticals is -2.29. Previous Next 3.3 News and Social Media Coverage News SentimentEagle Pharmaceuticals has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Eagle Pharmaceuticals this week, compared to 2 articles on an average week. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Eagle Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders28.90% of the stock of Eagle Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions85.36% of the stock of Eagle Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Eagle Pharmaceuticals is 4.44, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 136.21.Price to Earnings Ratio vs. SectorThe P/E ratio of Eagle Pharmaceuticals is 4.44, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 182.24.Price to Book Value per Share RatioEagle Pharmaceuticals has a P/B Ratio of 0.29. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaAltcoin FRENZY Alert…Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days… Click here now to register for the event (FOR FREE!) About Eagle Pharmaceuticals Stock (NASDAQ:EGRX)Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.Read More EGRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EGRX Stock News HeadlinesMarch 29, 2024 | americanbankingnews.comEagle Pharmaceuticals (NASDAQ:EGRX) Share Price Passes Below 200-Day Moving Average of $8.50March 29, 2024 | americanbankingnews.comEagle Pharmaceuticals (NASDAQ:EGRX) Stock Crosses Below Two Hundred Day Moving Average of $8.50March 29, 2024 | Crypto 101 Media (Ad)Major Elon Musk Crypto Leak RevealedReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.March 21, 2024 | americanbankingnews.comEagle Pharmaceuticals (NASDAQ:EGRX) Stock Crosses Below 200-Day Moving Average of $8.94February 29, 2024 | msn.comEagle Pharmaceuticals to cut 36% of workforceFebruary 22, 2024 | benzinga.comEagle Pharmaceuticals Stock (NASDAQ:EGRX), Short Interest ReportFebruary 22, 2024 | benzinga.comEagle Pharmaceuticals Stock (NASDAQ:EGRX) Dividends: History, Yield and DatesFebruary 9, 2024 | prnewswire.comEAGLE PHARMACEUTICALS SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Eagle Pharmaceuticals To Contact Him Directly To Discuss Their OptionsMarch 29, 2024 | Crypto Swap Profits (Ad)Did You Get Your Free Bitcoin Yet?And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.February 8, 2024 | stockhouse.comThe Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Eagle Pharmaceuticals, Inc. (EGRX)February 8, 2024 | markets.businessinsider.comLevi & Korsinsky Notifies Shareholders of Eagle Pharmaceuticals, Inc.(EGRX) of a Class Action Lawsuit and an Upcoming DeadlineFebruary 8, 2024 | markets.businessinsider.comShareholders that lost money on Eagle Pharmaceuticals, Inc.(EGRX) should contact Levi & Korsinsky about pending Class Action - EGRXFebruary 7, 2024 | markets.businessinsider.comClass Action Filed Against Eagle Pharmaceuticals, Inc. (EGRX) Seeking Recovery for Investors - Contact Levi & KorsinskyFebruary 6, 2024 | stockhouse.comSHAREHOLDER ALERT: Levi & Korsinsky Notifies Eagle Pharmaceuticals, Inc.(EGRX) Investors of a Class Action Lawsuit and Upcoming DeadlineFebruary 2, 2024 | stockhouse.com7-DAY DEADLINE ALERT: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmFebruary 2, 2024 | barrons.comEGRX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Eagle Pharmaceuticals, Inc. Shareholders to Contact the Firm!February 1, 2024 | stockhouse.comINVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmFebruary 1, 2024 | markets.businessinsider.comEGRX 9-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Eagle Pharmaceuticals (EGRX) Investors with Substantial Losses to Contact Firm Before Feb. 9th Deadline in Securities...January 31, 2024 | stockhouse.comINVESTOR ALERT: Levi & Korsinsky Notifies Eagle Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - EGRXJanuary 31, 2024 | barrons.comINVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmJanuary 30, 2024 | stockhouse.comINVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmJanuary 30, 2024 | stockhouse.comSHAREHOLDER ALERT: Levi & Korsinsky Notifies Eagle Pharmaceuticals, Inc. (EGRX) Investors of a Class Action Lawsuit and Upcoming DeadlineJanuary 28, 2024 | stockhouse.comSHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Eagle Pharmaceuticals, Inc. - EGRXJanuary 28, 2024 | markets.businessinsider.comEagle Pharmaceuticals (EGRX) Tells SEC It Improperly Accounted for Past Two Quarters and Defaults on Lender Agreement - Hagens BermanJanuary 23, 2024 | investing.comEagle Pharmaceuticals Inc (EGRX)January 19, 2024 | markets.businessinsider.comSHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmJanuary 18, 2024 | finanznachrichten.deEagle Pharmaceuticals, Inc.: Eagle Pharmaceuticals Provides Update on Bendamustine Intellectual Property PortfolioSee More Headlines Receive EGRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eagle Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2021Today3/29/2024Next Earnings (Estimated)4/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:EGRX CUSIPN/A CIK827871 Webwww.eagleus.com Phone(201) 326-5300FaxN/AEmployees134Year Founded2007Price Target and Rating Average Stock Price Target$17.00 High Stock Price Target$17.00 Low Stock Price Target$17.00 Potential Upside/Downside+224.4%Consensus RatingSell Rating Score (0-4)1.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)$1.18 Trailing P/E Ratio4.44 Forward P/E RatioN/A P/E GrowthN/ANet Income$35.64 million Net Margins6.04% Pretax Margin11.33% Return on Equity6.48% Return on Assets3.86% Debt Debt-to-Equity Ratio0.25 Current Ratio2.16 Quick Ratio1.67 Sales & Book Value Annual Sales$316.61 million Price / Sales0.21 Cash Flow$3.94 per share Price / Cash Flow1.33 Book Value$17.94 per share Price / Book0.29Miscellaneous Outstanding Shares12,990,000Free Float9,234,000Market Cap$68.07 million OptionableOptionable Beta0.42 Social Links Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Michael Graves (Age 61)Interim Principal Executive Officer & Executive Chairman of the Board Comp: $160kMr. Steven B. Ratoff (Age 81)Independent Director & Interim Chief Financial Officer Comp: $100kMr. Ryan DebskiExecutive VP, General Counsel & Chief Compliance OfficerMr. Daniel O'Connor (Age 44)Executive VP, Chief Strategy Officer & Head of Corporate Development Dr. Valentin R. Curt M.D.Senior Vice President of Clinical Drug DevelopmentDr. Gaozhong Zhu Ph.D.Senior Vice President of Pharmaceutical DevelopmentMs. Debra M. HussainSenior VP & Head of CommercialMr. Reed McClungExecutive Vice President of Oncology Business DevelopmentMore ExecutivesKey CompetitorsKezar Life SciencesNASDAQ:KZRKorro BioNASDAQ:KRROAnebulo PharmaceuticalsNASDAQ:ANEBMediciNovaNASDAQ:MNOVLandos BiopharmaNASDAQ:LABPView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Sold 5,473 shares on 3/11/2024Ownership: 4.914%Goldman Sachs Group Inc.Bought 32,571 shares on 3/1/2024Ownership: 1.492%GSA Capital Partners LLPBought 57,691 shares on 2/16/2024Ownership: 0.640%Vanguard Group Inc.Sold 5,473 shares on 2/15/2024Ownership: 4.912%Citadel Advisors LLCBought 3,800 shares on 2/15/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions EGRX Stock Analysis - Frequently Asked Questions Should I buy or sell Eagle Pharmaceuticals stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eagle Pharmaceuticals in the last year. There are currently 1 sell rating for the stock. The consensus among Wall Street analysts is that investors should "sell" EGRX shares. View EGRX analyst ratings or view top-rated stocks. What is Eagle Pharmaceuticals' stock price target for 2024? 1 equities research analysts have issued 1 year price objectives for Eagle Pharmaceuticals' stock. Their EGRX share price targets range from $17.00 to $17.00. On average, they expect the company's share price to reach $17.00 in the next twelve months. This suggests a possible upside of 224.4% from the stock's current price. View analysts price targets for EGRX or view top-rated stocks among Wall Street analysts. How have EGRX shares performed in 2024? Eagle Pharmaceuticals' stock was trading at $5.23 on January 1st, 2024. Since then, EGRX stock has increased by 0.2% and is now trading at $5.24. View the best growth stocks for 2024 here. When is Eagle Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, April 1st 2024. View our EGRX earnings forecast. How were Eagle Pharmaceuticals' earnings last quarter? Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) released its quarterly earnings results on Tuesday, November, 9th. The specialty pharmaceutical company reported $0.56 earnings per share for the quarter, beating analysts' consensus estimates of ($0.44) by $1.00. The specialty pharmaceutical company earned $39.85 million during the quarter, compared to analysts' expectations of $46.70 million. Eagle Pharmaceuticals had a net margin of 6.04% and a trailing twelve-month return on equity of 6.48%. During the same period in the prior year, the company posted $0.51 earnings per share. What other stocks do shareholders of Eagle Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Eagle Pharmaceuticals investors own include Gilead Sciences (GILD), Exelixis (EXEL), Teekay Tankers (TNK), AbbVie (ABBV), Intercept Pharmaceuticals (ICPT), Radius Recycling (RDUS), bluebird bio (BLUE), Clovis Oncology (CLVS), GW Pharmaceuticals (GWPH) and Incyte (INCY). Who are Eagle Pharmaceuticals' major shareholders? Eagle Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Brandes Investment Partners LP (5.74%), Vanguard Group Inc. (4.91%), Vanguard Group Inc. (4.91%), LSV Asset Management (3.02%), Dimensional Fund Advisors LP (1.90%) and Goldman Sachs Group Inc. (1.49%). Insiders that own company stock include Richard A Edlin and Scott Tarriff. View institutional ownership trends. How do I buy shares of Eagle Pharmaceuticals? Shares of EGRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:EGRX) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyMost important medical advance in 100 yearsThe Oxford ClubBuy this small stock before coming AI Tidal WaveChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eagle Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.